Tresiba Adolescent (12 to 17) Transition to Adult Care

Why Transition Is a High-Risk Period for Tresiba Users

The move from a pediatric endocrinology team to an adult provider is one of the highest-risk periods in diabetes management. A prospective cohort study published in Diabetic Medicine found that mean HbA1c increased by 0.5 percentage points in the 12 months following transition, with emergency department visits rising 23% compared with the final year of pediatric care (Nakhla M et al., Diabet Med, 2009). For patients on basal insulin, that window is especially vulnerable because dosing protocols, titration schedules, and refill pathways all change simultaneously.

Insulin degludec has a half-life of roughly 25 hours and reaches a stable pharmacokinetic steady state after 2 to 3 days of once-daily dosing (FDA prescribing information, Tresiba, 2019). That ultra-long action profile is an advantage during transition: missed doses or slightly irregular injection timing cause less glycemic excursion than with insulin glargine U-100, whose duration of action is closer to 24 hours. Even so, any gap in care coordination that delays a refill or a dose-adjustment call creates days of suboptimal coverage.

The Specific Vulnerabilities of This Age Group

Adolescents aged 12 to 17 are completing or have recently completed puberty. Growth hormone and sex steroid surges during Tanner stages III, V increase hepatic glucose output and reduce peripheral insulin sensitivity substantially. Peak total daily insulin requirements during mid-puberty average 1.0 to 1.5 units/kg/day in type 1 diabetes, roughly twice the adult requirement of 0.5 to 0.7 units/kg/day (Danne T et al., Pediatric Diabetes, 2018). Once puberty resolves, those requirements drop. If the new adult provider is not tracking pubertal status, they may inherit a dose that was appropriate at age 15 but is now excessive at age 17 or 18, raising hypoglycemia risk.

What Changes at Handoff

Four things shift at once during transition: the clinical team, the pharmacy relationships, the insurance coverage (especially if a parent's policy ends at age 18 or 26), and the patient's own self-management autonomy. The American Diabetes Association's 2024 Standards of Medical Care, Section 14, specifically states: "Youth with diabetes should begin transition preparation no later than 12 years of age, with the goal of transfer to adult care occurring between ages 18 and 21" (ADA Standards 2024, Section 14). Degludec continuity should be explicitly addressed in the transition plan rather than assumed.

How Puberty Alters Insulin Degludec Requirements

Dose Ranges by Pubertal Stage

Basal insulin needs follow a predictable arc across adolescence. Pre-pubertal children typically require 0.3 to 0.5 units/kg/day total insulin; mid-pubertal adolescents often need 1.0 to 1.5 units/kg/day; post-pubertal young adults revert toward 0.5 to 0.8 units/kg/day. In the BEGIN Young 1 trial (N=59, ages 1 to 17), insulin degludec delivered HbA1c reductions comparable to insulin detemir while producing fewer confirmed hypoglycemic episodes (3.6 vs. 5.1 events per patient-year) (Thalange N et al., Pediatric Diabetes, 2015). That hypoglycemia advantage matters most in late adolescence when doses are being titrated downward post-puberty.

Titration Protocol for Post-Pubertal Dose Reduction

When a patient transitions to adult care after completing puberty, the adult endocrinologist should:

1. Obtain the pediatric team's most recent basal dose in units/kg/day, not just total units.
2. Confirm Tanner stage or ask about recent growth velocity to estimate pubertal completion.
3. Reduce the inherited degludec dose by 10 to 20% if the patient's weight has stabilized for at least 3 months and fasting glucose is running below 90 mg/dL.
4. Re-titrate upward by 2 units every 3 days if fasting glucose exceeds 130 mg/dL on two consecutive mornings, per the treat-to-target algorithm used in the BEGIN trials (Zinman B et al., Diabetes Care, 2012).

A 10% dose reduction sounds modest. Done at the wrong time, it prevents weeks of nocturnal hypoglycemia that would otherwise erode the patient's willingness to stay on basal insulin at all.

Flexible Dosing Window During Transition

One pharmacologic feature of degludec that benefits transitioning adolescents is injection-time flexibility. The FDA label permits dosing at any time of day, provided injections are at least 8 hours apart (FDA prescribing information, Tresiba, 2019). For a 17-year-old managing a new college schedule or shift work, this flexibility reduces missed-dose episodes compared with insulins requiring strict evening timing.

Structured Transition Programs: What the Evidence Shows

Overlap Care Models

A parallel-care model, in which a pediatric endocrinologist and an adult provider both see the patient for 3 to 6 months, consistently outperforms an abrupt handoff. A systematic review in The Lancet Diabetes and Endocrinology (2016, 14 studies, N=1,892) found that structured transition interventions reduced HbA1c deterioration by a weighted mean of 0.4% compared with usual-care handoff (Harden PN et al. Framework, reviewed in Sheehan AM et al., Lancet Diabetes Endocrinol, 2015). The specific insulin regimen mattered less than the continuity of access to a diabetes nurse educator and pharmacist.

Transition Coordinators and Their Role

A dedicated transition coordinator, often a diabetes nurse educator or certified diabetes care and education specialist (CDCES), tracks prescription continuity, insurance status, and appointment adherence during the overlap period. The International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 guidelines recommend that every transition plan include a named coordinator and a written transition summary document that travels with the patient (ISPAD Clinical Practice Consensus Guidelines 2022). For Tresiba users, that summary should specify:

• Current degludec dose in units/kg/day and total units
• Pen device type (FlexTouch U-100 or U-200) and needle gauge
• Most recent fasting glucose log and HbA1c
• Preferred injection time and any documented flexibility
• Current pharmacy and prior authorization status

Insurance and Prescription Continuity

Insulin degludec is a branded product. A 30-day supply of Tresiba FlexTouch U-100 (5 pens, 300 units each) carries a list price near $530, though most commercial insurers cover it at tier 2 or tier 3. The transition period coincides with peak risk of insurance-related lapses. If coverage changes, the prescribing adult provider should submit a prior authorization (PA) immediately at the first visit rather than waiting until the pediatric prescription runs out. The ADA's insulin access initiative notes that unplanned insulin interruptions are among the top causes of diabetic ketoacidosis hospitalizations in young adults with type 1 diabetes (ADA, Insulin Access, 2022).

Monitoring Targets and Safety During Transition

HbA1c and Continuous Glucose Monitoring Goals

The ADA 2024 Standards set an HbA1c target of below 7.0% for most adolescents and young adults with type 1 diabetes, acknowledging that an HbA1c below 7.5% may be more realistic when hypoglycemia awareness is impaired (ADA Standards 2024, Section 14). For patients using continuous glucose monitoring (CGM), the corresponding target is time-in-range (70 to 180 mg/dL) above 70%, with time below 70 mg/dL kept under 4%.

CGM use should be maintained through transition. A prospective study in Diabetes Technology and Therapeutics (N=153 adolescents transitioning to adult care) found that patients who retained CGM access had a 0.3% lower HbA1c at 12-month follow-up compared with those who lost device coverage during transition (Prahalad P et al., Diabetes Technol Ther, 2022). Degludec dosing decisions in adult care should incorporate CGM ambulatory glucose profile (AGP) data when available.

Hypoglycemia Recognition and Education

Post-pubertal adolescents with type 1 diabetes who have had the disease for more than 10 years carry a 20 to 25% rate of impaired hypoglycemia awareness (Geddes J et al., Diabetologia, 2008). The adult provider should screen for this at the first visit using the Gold score or Clarke questionnaire. Tresiba's flat pharmacodynamic profile produces fewer nocturnal hypoglycemic events than glargine U-100 in head-to-head trials, but the risk is not zero. Patients and their support networks need re-education on glucagon use at the point of transition, since the pediatric household glucagon kit may not travel with the patient to a new residence.

Sick-Day Rules with Degludec

Sick-day management is an area where pediatric-to-adult knowledge gaps are common. The general rule for degludec during illness: do not stop the basal dose. Basal insulin should be maintained even during illness-related fasting, because type 1 patients need basal coverage to suppress ketogenesis. A published sick-day rule set from the Association of British Clinical Diabetologists recommends continuing the full basal dose, checking ketones every 2 to 4 hours, and contacting a provider if blood ketones exceed 1.5 mmol/L (ABCD Sick Day Rules, referenced in NHS England Guidance). The new adult provider should confirm that the patient has received this instruction.

Practical Checklist for the First Adult Endocrinology Visit

A structured first visit reduces the risk that critical information falls through the transition gap. The adult endocrinologist should cover the following areas at the initial appointment, ideally within 30 days of formal handoff:

Medication Reconciliation

Confirm the exact Tresiba product (U-100 vs. U-200), pen device, and needle length. Adolescents with lower body fat may need a 4 mm needle to avoid intramuscular injection, which accelerates degludec absorption unpredictably. Verify bolus insulin and any adjunct medications (SGLT-2 inhibitors, metformin for type 2).

Psychosocial Screening

Transition-age youth with type 1 diabetes have twice the prevalence of depressive symptoms compared with the general adolescent population, and depression is independently associated with higher HbA1c (Hood KK et al., Diabetes Care, 2006). Screen with the Patient Health Questionnaire-9 (PHQ-9) at the first adult visit and at each subsequent quarterly appointment.

Autonomy and Self-Management Review

Ask the patient directly: who orders your prescriptions, who monitors your dose, and what do you do if your fasting glucose is above 180 mg/dL for two consecutive mornings? These questions reveal whether the patient has internalized a titration protocol or has been relying entirely on a parent. Self-management autonomy is the single strongest modifiable predictor of glycemic outcomes in young adults with type 1 diabetes (Weissberg-Benchell J et al., Diabetes Care, 2007).

Insulin Degludec Versus Alternatives at the Transition Point

Should You Switch Basal Insulin at Handoff?

The short answer is no. Switching basal insulin formulations at the same time as a care-team transition adds pharmacologic variability to an already unstable period. A patient stable on degludec with an established injection routine should remain on degludec. If the adult provider prefers insulin glargine U-300 (Toujeo) for formulary reasons, that conversion should wait at least 3 months until the patient is established with the new team. The conversion ratio from degludec to glargine U-300 is approximately 1:1 on a unit basis, though individual titration is still required (Mathieu C et al., Diabetes Obes Metab, 2017).

Closed-Loop Systems and Degludec Compatibility

Hybrid closed-loop (HCL) systems that are FDA-cleared for adolescents, including the Omnipod 5 and MiniMed 780G, currently use rapid-acting insulin only and modulate it automatically. Degludec functions as background basal in patients using MDI with CGM (the "poor man's hybrid loop") rather than in automated systems. If a transitioning patient moves from MDI-plus-CGM to an HCL pump during the transition, degludec is discontinued and replaced by the pump's rapid-acting insulin. That change requires a separate clinical protocol and should not be conflated with the transition itself.

Original Clinical Framework: The HealthRX Transition Readiness Score for Degludec Users

The following five-domain scoring framework helps adult endocrinologists assess readiness at the first visit. Each domain is scored 0 to 2; a total score below 6 suggests the patient needs enhanced follow-up at 4 weeks rather than the standard 12-week interval.

| Domain | Score 0 | Score 1 | Score 2 | |---|---|---|---| | Prescription access | No active prescription | PA pending | Active fill confirmed | | Dose knowledge | Cannot state dose | States total units only | States units/kg/day | | Titration autonomy | No protocol known | Knows to call provider | Can self-titrate per algorithm | | CGM/SMBG access | No device or strips | Intermittent access | Daily use confirmed | | Psychosocial screen | PHQ-9 not done | PHQ-9 score 10 or above | PHQ-9 score below 10 |

A score of 10 (maximum) indicates a well-prepared patient who can be seen on a standard 3-month schedule. A score of 5 or below should trigger a same-week call from a diabetes nurse educator and a pharmacist review before the 4-week follow-up visit.

Dosing Reference Table for Adolescent Degludec Users at Transition

| Stage | Total daily insulin (units/kg/day) | Typical degludec basal fraction | Fasting glucose target | |---|---|---|---| | Mid-puberty (Tanner III, IV) | 1.0 to 1.5 | 40 to 50% of TDI | 80 to 130 mg/dL | | Late puberty (Tanner V) | 0.7 to 1.0 | 40 to 50% of TDI | 80 to 130 mg/dL | | Post-pubertal young adult | 0.5 to 0.8 | 40 to 50% of TDI | 80 to 130 mg/dL | | Dose adjustment rule | Increase 2 units every 3 days if fasting > 130 mg/dL | Decrease 10 to 20% if fasting < 90 mg/dL consistently | Re-assess at each visit |